Compare QCLS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QCLS | BOLD |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.1M | 36.5M |
| IPO Year | N/A | 2024 |
| Metric | QCLS | BOLD |
|---|---|---|
| Price | $4.03 | $1.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 396.5K | 63.3K |
| Earning Date | 04-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.50 | $0.96 |
| 52 Week High | $8.17 | $1.68 |
| Indicator | QCLS | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 51.86 | 50.23 |
| Support Level | $3.86 | $1.40 |
| Resistance Level | $4.66 | $1.53 |
| Average True Range (ATR) | 0.28 | 0.05 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 53.68 | 38.46 |
Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.